Close

Anti-ITFG2 DNA-encoded mAb (DMAb), pVAX1 (DMAb-1035-YY)


All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

This product is the plasmid containing an encoded anti-ITFG2 DMAb sequence. The plasmid can drive transcription and in vivo translation of the desired antibody.

  Add to Cart

Specifications

  • Target
  • ITFG2
  • Vector Name
  • pVAX1
  • Vector Description
  • pVAX1 was originally designed for the development of DNA vaccines. Its eukaryotic DNA sequences limited to the expression of desired sequence so that minimize the possibility of chromosomal integration. This vector has been widely used for the construction of DMAb plasmid.
  • Vector Promoter
  • CMV
  • Vector Tag or Fusion
  • Untagged
  • Delivery Method
  • Transfection
  • Cloning Method
  • Restriction Enzyme ⁄ MCS
  • Constitutive or Inducible System
  • Constitutive
  • Storage
  • Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term.
  • Background
  • DNA-encoded mAb (DMAb) technology is a novel approach for a direct in vivo production of desired biologically active immunoglobulins according to the plasmid DNA delivery into tissue where the delivered plasmid containing an encoded antibody sequence. Compared with the traditional mAb, DMAb can be functionally equivalent with additional advantages such as expression profiles, glycosylation, as well as no reliance on in vivo tissue culture and costly or time-consuming production systems. The DMAb technology may provide a novel, simple, less frequent, cost-effective approach for therapeutics.

Target

Sub CAT. DMAb Clone DMAb Host Target Species DMAb Isotype DMAb Immunogen  
DMAb-1035-YY CBYY-I2012 Mouse Human Full length human recombinant protein of human ITFG2 (NP_060933)
DMAb-1036-YY CBYY-I2013 Mouse Human Full length human recombinant protein of human ITFG2(NP_060933)
DMAb-1037-YY CBYY-I2016 Mouse Human Full length human recombinant protein of human ITFG2(NP_060933)
DMAb-1038-YY CBYY-I2017 Mouse Human Full length human recombinant protein of human ITFG2 (NP_060933)
DMAb-1016-YY CBYY-I1870 Mouse Human Full length human recombinant protein of human ITFG2 (NP_060933)
DMAb-1017-YY CBYY-I1871 Mouse Human Full length human recombinant protein of human ITFG2 (NP_060933)
DMAb-1018-YY CBYY-I1872 Mouse Human Full length human recombinant protein of human ITFG2 (NP_060933)
DMAb-1077-LY 2H5 Mouse Human
DMAb-1045-YY CBYY-I2054 Mouse Human Full length human recombinant protein of human ITFG2(NP_060933)
DMAb-1040-YY CBYY-I2032 Mouse Human Full length human recombinant protein of human ITFG2 (NP_060933)
DMAb-1041-YY CBYY-I2041 Mouse Human Full length human recombinant protein of human ITFG2 (NP_060933)
DMAb-1803-FY CBFYM-1158 Mouse Human IgG1 Full length human recombinant protein of human ITFG2 (NP_060933) produced in HEK293T cell

Customer Reviews and Q&As

There are currently no customer reviews or questions for Anti-ITFG2 DNA-encoded mAb (DMAb), pVAX1 (DMAb-1035-YY). Click the button below to contact us or submit your feedback about this product.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Related Products

Online Inquiry

For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Key Updates
Newsletter NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER
New Solution NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION
NOVEL SOLUTION NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY
NEW TECHNOLOGY NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION
Receive our latest news and insights.